Here are relevant reports on : cancer-immunotherapy-market
-
Prostate Cancer Therapeutics Market (2010-2020) (Opportunity Analysis, Pipeline Assessment and Global Market Forecast)
Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Global Colorectal Cancer Market (2010-2015)
2008 saw almost 12 million patients diagnosed with cancer. Despite, increasing technological advancements and research the deaths due to cancer were about 8 million people in 2008. Lung cancer accounts for the highest mortality rate.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Global Breast Cancer Drugs Market
There are about one million new cases of breast cancer every year. Breast cancer accounts for about 10% of world wide cancer. There has been significant increase in awareness levels with respect to impact on survival rates incase of early diagnosis. Therefore, opening novel opportunities for breast cancer drugs market.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Renal Cancer Drugs Market by therapy (targeted therapy, chemotherapy, and immunotherapy), drug class (anti-angiogenesis, mTOR inhibitors, interleukin, and immune checkpoint inhibitors), indication (renal cell carcinoma, urothelial carcinoma, and others), distribution channel (hospitals, specialty & retail pharmacies and others), and region (North America, Europe, Asia Pacific and Rest of the World (RoW) which includes Latin America and Middle East & Africa) – global forecasts to 2027
The renal cancer drugs market is projected to reach USD 8 billion by 2027 from USD 6 billion in 2022, at a CAGR of 6% during the forecast period.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Flow Cytometry Market by Technology (Cell-based, Bead-Based), Product & Service (Analyzer, Sorter, Consumables (Antibodies, Assays, Kits), Software), Application (Research (Stem Cell), Clinical (Cancer)), End User (Hospital) - Global Forecast to 2033
The global flow cytometry market, valued at US$4.87 billion in 2024, stood at US$5.06 billion in 2025 and is projected to advance at a resilient CAGR of 8.7% from 2025 to 2033, culminating in a forecasted valuation of US$9.85 billion by the end of the period. The major factors driving the growth in the flow cytometry market include advancements in technology, increasing adoption of flow cytometry products in clinical diagnostics, rising prevalence of chronic diseases, growing biopharmaceutical R&D, and the need for precision medicine.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Real World Evidence Solutions Market by Component (Datasets (Claims, Clinical, Pharmacy, Genomics), Application (Drug/Device Development (Cancer, Cardio, Neuro), Reimbursement), End User (Pharma, Medtech, Payers, Provider), Region - Global Forecast to 2030
The global real world evidence solutions market, valued at US$4.74 billion in 2024, stood at US$5.42 billion in 2025 and is projected to advance at a resilient CAGR of 14.8% from 2025 to 2030, culminating in a forecasted valuation of US$10.8 billion by the end of the period.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Immuno Oncology Assays Market Size, Share & Trends by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications (Lung, Breast, Colorectal, Bladder, Melanoma), Application (Research, Diagnostics) - Global Forecast to 2026
The size of global immuno oncology assays market in terms of revenue was estimated to be worth USD 4.4 billion in 2021 and is poised to reach USD 7.9 billion by 2026, growing at a CAGR of 12.5% from 2021 to 2026. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
- Published: April 2021
- Price: $ 4950
- TOC Available:
-
Gastrointestinal Products Market | Gastroenterology Products Market by Devices (Endoscopy, Ablation system, Motility testing, Biopsy devices, Stenting devices, pH monitoring), Diseases (GERD), (IBD), Gastrointestinal cancer), End-User (Hospitals, ASC) - Global Forecast to 2029
The global gastrointestinal products market, valued at US$13.8 million in 2023, stood at US$14.7 million in 2024 and is projected to advance at a resilient CAGR of 6.1% from 2024 to 2029, culminating in a forecasted valuation of US$19.7 million by the end of the period. Market growth can be attributed to the growing prevalence of gastrointestinal diseases such as Crohn's disease, ulcerative colitis, irritable bowel syndrome (IBS), and colorectal cancer, which drives the demand for diagnostic and therapeutic products.
- Published: August 2024
- Price: $ 4950
- TOC Available:
-
Pain Management Devices Market by Type (Neurostimulation, Infusion Pump, Ablation), Application (Neuropathic, Musculoskeletal, Cancer pain), Mode of Purchase (Prescription, OTC), By End user (Hospital, Physiotherapy, Home care) - Global Forecast to 2029
The global pain management devices market, valued at US$3491.0 million in 2023, stood at US$3,768.6 million in 2024 and is projected to advance at a resilient CAGR of 9.1% from 2024 to 2029, culminating in a forecasted valuation of US$5,835.8 million by the end of the period. The increasing prevalence of chronic pain conditions, coupled with a growing number of surgical procedures, rising technological advancements, an expanding aging patient population, an established reimbursement framework promoting access to pain management devices, and emerging market opportunities are expected to drive market growth during the forecast period.
- Published: October 2024
- Price: $ 4950
- TOC Available:
-
Viral Vector & Plasmid DNA Manufacturing Market by Type (Viral Vector (Retroviruses, Adenoviruses, AAV, Lentiviruses), Plasmid DNA), Workflow (Upstream, Downstream), Application (Cell & Gene Therapy), Diseases (Cancer), End User - Global Forecast to 2028
The global viral vector manufacturing market, valued at US$4.8 billion in 2022, stood at US$5.5 billion in 2023 and is projected to advance at a resilient CAGR of 18.2% from 2023 to 2028, culminating in a forecasted valuation of US$12.8 billion by the end of the period. The growth of this market is majorly driven by g rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, and effectiveness of viral vectors in gene therapy delivery.
- Published: June 2023
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
